Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sincere CoTSE:7782 +0.21%77 10-Year RORE % is 0.00 as of Dec. 2025. GuruFocus rates TSE:7782 with a GF Score™ of 77/100 and a GF Value™ of 円686.49 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 426 Medical Devices & Instruments companies, Sincere Co ranks worse than 234741.55% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Sincere Co's 10-Year RORE % for the quarter that ended in Dec. 2025 was 0.00%.
The industry rank for Sincere Co's 10-Year RORE % or its related term are showing as below:
TSE:7782's 10-Year RORE % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.145 * Ranked among companies with meaningful 10-Year RORE % only.
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Sincere Co 10-Year RORE % Related Terms
Sincere Co 10-Year RORE % Historical Data
* Premium members only.
The historical data trend for Sincere Co's 10-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7782 vs ISRG, BDX, MDLN: 10-Year RORE % Comparison
For the Medical Instruments & Supplies subindustry, Sincere Co's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sincere Co 10-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sincere Co's 10-Year RORE % distribution charts can be found below:
* The bar in red indicates where Sincere Co's 10-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 10-year before.
Sincere Co (TSE:7782) has a 10-Year RORE % of 0.00 as of Dec. 2025. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Sincere Co and its competitors. According to the industry distribution chart, Sincere Co ranks #999999 out of 426 companies in the Medical Devices & Instruments industry.
Is Sincere Co's 10-Year RORE % too high?
Sincere Co's current 10-Year RORE % is 0.00. Based on the distribution chart, Sincere Co ranks #999999 out of 426 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sincere Co has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sincere Co's 10-Year RORE % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sincere Co ranks #999999 out of 426 companies for 10-Year RORE %. This places Sincere Co in the lower half of its industry. The industry median 10-Year RORE % is 1.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year RORE % for a Medical Devices & Instruments company?
The median 10-Year RORE % among Medical Devices & Instruments companies is 1.15, based on 426 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year RORE % mean?
A high 10-Year RORE % can signal that a stock is expensive relative to its fundamentals. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Sincere Co and its competitors. For the Medical Devices & Instruments industry, the median 10-Year RORE % is 1.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sincere Co's current 10-Year RORE % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sincere Co stock overvalued right now?
Based on GuruFocus' analysis, Sincere Co (TSE:7782) is currently considered Significantly Undervalued. The stock's GF Value™ is 円686.49, compared to a current price of 円470.00 — trading 31.5% below its estimated fair value. The current 10-Year RORE % is 0.00. Sincere Co's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year RORE % calculated?
10-Year RORE % is calculated from a company's financial statements. For Sincere Co (TSE:7782), the current 10-Year RORE % is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sincere Co (TSE:7782) Overvalued in 2026?
Based on GuruFocus' analysis, Sincere Co stock appears to be undervalued.
The current stock price of 円470.00 is trading 31.5% below its estimated GF Value™ of 円686.49.
GuruFocus considers Sincere Co to be Significantly Undervalued.
Key valuation signals for TSE:7782:
10-Year RORE %: 0.00
GF Value™: 円686.49 vs. price of 円470.00 (31.5% below fair value)
No single metric tells the full story. See the TSE:7782 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sincere Co Ltd is a Japanese firm engaged in the manufacturing and sale of contact lens.As a company that manufactures and sells contact lenses, which are high-regulated medical devices, it place the highest priority on product safety and quality control, while working closely with company's customers to develop a variety-of-products and sell them at affordable prices to please as many customers as possible. The company opperates domestically as well as internationally.
77GF Score
Get the complete analysis for TSE:7782
10-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7782 has been successfully added to your 
